MA44413A - Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications - Google Patents

Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications

Info

Publication number
MA44413A
MA44413A MA044413A MA44413A MA44413A MA 44413 A MA44413 A MA 44413A MA 044413 A MA044413 A MA 044413A MA 44413 A MA44413 A MA 44413A MA 44413 A MA44413 A MA 44413A
Authority
MA
Morocco
Prior art keywords
complications
cancer
pharmaceutical composition
composition used
therapeutic treatment
Prior art date
Application number
MA044413A
Other languages
English (en)
Inventor
Nitcheu Guy Faustin Monkam
Original Assignee
Nitcheu Guy Faustin Monkam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1771115A external-priority patent/FR3058060B1/fr
Application filed by Nitcheu Guy Faustin Monkam filed Critical Nitcheu Guy Faustin Monkam
Publication of MA44413A publication Critical patent/MA44413A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044413A 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications MA44413A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1670645A FR3058058A1 (fr) 2016-10-31 2016-10-31 Composition pharmaceutique comprenant en tant que principe actif une combinaison de beta-elemene, de lupeol et du 2-hydroxycinnamaldehyde et/ou du 2-benzoyloxycinnalmaldehyde et/ou beta-sitosterol
FR1670666A FR3058059B1 (fr) 2016-10-31 2016-11-08 Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
FR1771115A FR3058060B1 (fr) 2016-10-31 2017-10-23 Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.

Publications (1)

Publication Number Publication Date
MA44413A true MA44413A (fr) 2021-03-17

Family

ID=58401825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044413A MA44413A (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications

Country Status (11)

Country Link
US (1) US20240197755A1 (fr)
EP (1) EP3429568A1 (fr)
KR (1) KR20190077449A (fr)
CN (1) CN109562080B (fr)
CA (1) CA3043456A1 (fr)
FR (2) FR3058058A1 (fr)
IL (1) IL266623A (fr)
MA (1) MA44413A (fr)
MX (1) MX2019003685A (fr)
WO (1) WO2018078539A1 (fr)
ZA (1) ZA201902910B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109438166B (zh) * 2018-11-08 2021-06-04 石药集团远大(大连)制药有限公司 (1S,2S,4S)-β-榄香烯及其制备方法和应用
FR3100128B1 (fr) * 2019-08-30 2022-02-18 Nitcheu Guy Faustin Monkam Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
JP2023504821A (ja) * 2019-12-03 2023-02-07 四川弘合生物科技有限公司 エレメンを含む医薬組成物、その調製方法、及びその使用
CN111909897B (zh) * 2020-08-14 2021-12-21 宜兴市人民医院 Ruvbl2在调控人脐带间质干细胞增殖和/或分化中的应用
CN113018312B (zh) * 2021-01-11 2022-12-09 南开大学 一种降低肿瘤辐射抗性的纳米放疗增敏剂及其制备方法和应用
US20220362227A1 (en) * 2021-05-11 2022-11-17 Roseman University Of Health Sciences Composition of phytonutrients for diabetes management
KR20230167257A (ko) 2022-05-31 2023-12-08 전남대학교산학협력단 1개 이상의 유효성분을 포함하는 신장섬유화증 예방, 개선 또는 치료용 조성물
CN117482049B (zh) * 2023-12-29 2024-03-26 中国人民解放军总医院海南医院 一种抗肿瘤组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22846A1 (es) * 1998-12-29 2003-04-28 Ct De Quimica Farmaceutica Composiciones farmacéuticas y nutricionales a partir de extractos de mangifera indica l

Also Published As

Publication number Publication date
EP3429568A1 (fr) 2019-01-23
FR3058059B1 (fr) 2020-07-10
FR3058058A1 (fr) 2018-05-04
WO2018078539A1 (fr) 2018-05-03
MX2019003685A (es) 2019-09-26
CN109562080A (zh) 2019-04-02
US20240197755A1 (en) 2024-06-20
ZA201902910B (en) 2020-06-24
KR20190077449A (ko) 2019-07-03
IL266623A (en) 2019-07-31
FR3058059A1 (fr) 2018-05-04
CA3043456A1 (fr) 2018-05-03
CN109562080B (zh) 2022-12-20

Similar Documents

Publication Publication Date Title
MA44413A (fr) Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3471735A4 (fr) Compositions pharmaceutiques et leur utilisation pour le traitement du cancer et des maladies auto-immunes
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43807A (fr) Préparation et composition de traitement de tumeurs malignes
MA50409A (fr) Polythérapies pour le traitement du cancer
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA52499A (fr) Associations pour le traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA48791A (fr) Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies